中国临床医生杂志2020年第48卷第8期
908
论著
··
顺铂腹腔灌注联合静脉化疗治疗胃癌腹腔转移的
临床效果
肖谜，王妹兴（上海市闵行区肿瘤医院，上海200240）
摘要：目的研究顺铂腹腔灌注联合静脉化疗治疗胃癌腹腔转移的临床疗效。方法选择2015年4月至2018年4月上海市闵行
区肿瘤医院收治的胃癌腹腔转移患者60例，按随机数字表法分为观察组与对照组各30例。对照组行静脉化疗治疗，观察组腹腔
灌注顺铂联合静脉化疗治疗。对比两组治疗后临床疗效、存活时间及治疗期间不良反应发生情况，另外对比两组治疗前后欧洲
癌症治疗研究组织生活质量测定量表（qualityoflifescaleofEuropeanOrganizationforResearchandTreatmentofCancer，EORTC
QLQ-C30）评分。结果观察组治疗后有效率70.00%、控制率93.33%，显著高于对照组（43.33%、73.33%），差异有显著性
（P＜0.05）。两组患者治疗后均行12个月随访，期间无失访；观察组中位生存时间显著高于对照组，差异有显著性（P＜
0.05）；观察组治疗后6、9、12个月存活率显著高于对照组，差异有显著性（P＜0.05）。观察组治疗后功能评分、症状评分、
整体生活质量评分、单项测量项目评分显著高于治疗前及对照组治疗后，差异有显著性（P＜0.05）。两组不良反应总发生率对
比，差异无显著性（P＞0.05）。结论顺铂腹腔灌注联合静脉化疗治疗胃癌腹腔转移能够提高临床治疗效果及患者的生活质
量，同时还能延长患者生存时间，具有较高的临床应用价值。
关键词：胃癌；腹腔转移；顺铂；腹腔灌注；静脉化疗
中图分类号：R735.2文献标识码：A文章编号：2095-8552（2020）08-0908-04
doi:10.3969/j.issn.2095-8552.2020.08.010
ObservationontheefficacyofCisplatinintraperitonealperfusioncombinedwithintravenouschemotherapyfor
gastriccancerwithabdominalmetastasis
ShanghaiMinhangDistrictTumorHospital,Shanghai200240,China
XiaoMi,WangXingmei()
Abstract:ObjectiveTostudytheclinicalef?cacyofcisplatinum-intraperitonealperfusioncombinedwithintravenouschemotherapyin
thetreatmentofperitonealmetastasisofgastriccancer.MethodAtotalof60patientswithperitonealmetastasisofgastriccancerwhowere
treatedinourhospitalfromApril2015toApril2018wereselected,andweredividedintoobservationgroup(n=30)andcontrolgroup
n
(=30)byrandomnumbertablemethod.Thecontrolgroupwastreatedwithintravenouschemotherapy,andtheobservationgroupwas
treatedwithintraperitonealDDPcombinedwithintravenouschemotherapy.Clinicalef?cacy,survivaltimeandadversereactionsduring
treatmentwerecomparedbetweenthetwogroups.Inaddition,qualityoflifescaleofEuropeanOrganizationforResearchandTreatment
ofCancer(QLQ-C30)scoresofcancerpatientsbeforeandaftertreatmentwerecomparedbetweenthetwogroups.ResultAftertreatment,
theeffectiverateandcontrolrateoftheobservationgroupwas70.00%and93.33%respectively,whichwassignificantlyhigherthan
P
thoseofthecontrolgroup(43.33%and73.33%,＜0.05).Twogroupsofpatientswerefollowedupfor12monthsaftertreatment,during
whichtherewasnolossoffollow-up.Themediansurvivaltimeoftheobservationgroupwassigni?cantlyhigherthanthatofthecontrol
group,thedifferencewasstatisticallysigni?cant(P＜0.05).Thesurvivalrateof6,9and12monthsaftertreatmentintheobservationgroup
wassigni?cantlyhigherthanthatinthecontrolgroup(P＜0.05).Thefunctionalscores,symptomscores,overallqualityoflifescores,
andscoresofindividualmeasurementitemsintheobservationgroupweresigni?cantlyhigherthanthosebeforeandaftertreatment(P
P
＜0.05).Therewasnosignificantdifferenceinthetotalincidenceofadversereactionsbetweenthetwogroups(＞0.05).Conclusion
DDPintraperitonealperfusioncombinedwithintravenouschemotherapyinthetreatmentofabdominalmetastasisofgastriccancercould
improvetheclinicalef?cacyandqualityoflifeofpatients,butalsoprolongthesurvivaltimeofpatients,whichhadhighclinicalvalue.
Keywords:Gastriccancer;Abdominalmetastasis;Cisplatin;Intraperitonealperfusion;Intravenouschemotherapy
通信作者，E-mail:13661816380@163.com
journalofmedicine,2001,344(19):1434-1441.[36]LIXL,WANGL,BIXL,etal.Gushukangexertsosteopreserve
[31]JOHANSSONH,SIGGEIRSDóTTIRK,HARVEYNC,etal.effectsbyregulatingvitaminDandcalciummetabolismin
Imminentriskoffractureafterfracture[J].OsteoporosInt,2017,ovariectomizedmice[J].JBoneMinerMetab,2019,37(2):224-234.
28(3):775-780.[37]ZHUHM,QINL,GARNEROP,etal.Thefirstmulticenter
[32]CUMMINGSSR,SANMARTINJ,MCCLUNGMR,etal.andrandomizedclinicaltrialofherbalFufangfortreatmentof
Denosumabforpreventionoffracturesinpostmenopausalwomenpostmenopausalosteoporosis[J].OsteoporosisInternational,2012,
withosteoporosis[J].NEnglJMed,2009,361(8):756-765.23(4):1317-1327.
[33]HUYNHALH,BAKERST,STEWARDSONAJ,etal.[38]徐静,孙建新.坤泰胶囊对去卵巢大鼠骨质疏松防治效果的实
Denosumab-associatedhypocalcaemia:incidence,severityandpatient验研究[J].现代中西医结合杂志,2015,24(26):2873-2875.
characteristicsinatertiaryhospitalsetting[J].Pharmacoepidemiology[39]毛旭东,王涵.浅谈坤泰胶囊在围绝经期妇女骨折治疗中的临
andDrugSafety,2016,25(11):1274-1278.床疗效[J].首都食品与医药,2019,26(4):39.
[34]史晓林,王和鸣,高毅,等.绝经后骨质疏松症(骨痿)中医药诊疗[40]章轶立,廖星,刘福梅,等.仙灵骨葆胶囊上市后用药安全性系
指南(2019年版)[J].中医正骨,2020,32(2):1-13.统评价[J].中国中药杂志,2017,42(15):2845-2856.
[35]黄莉,李悦,邱建利,等.骨疏康治疗原发性骨质疏松症随机对照收稿日期：2020-05-28；修回日期：2020-06-08
临床研究Meta分析[J].辽宁中医药大学学报,2016,18(4):85-88.（本文编辑：习秋云）
http://guide.medlive.cn/ |
|
